The frequency of uMRD in Japanese patients with CLL after 24 months of treatment with Venetoclax plus/minus Rituximab in the 2L+ in the real-world setting

The frequency of uMRD in Japanese patients with CLL after 24 months of treatment with Venetoclax plus/minus Rituximab in the 2L+ in the real-world setting - Japan CLL-MRD study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050967

Enrollment

Registered

2023-05-08

Start date

2023-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphocytic Leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult (18 years old or more) patients diagnosed with relapsed/refractory (2L+) CLL in Japan based on iwCLL criteria at the time of informed concent 2. Patients during treatment with Venetoclax plus/minus Rituximab for 24 months who are not treated with any other concurrent CLL treatment 3. Patients who are expected to visit the hospital at + 3 months after treatment with Venetoclax plus/minus Rituximab for 24 months 4. Patients who give informed consent (or by her/his guardian) for participating this study

Exclusion criteria

Exclusion criteria: 1. Patients with no data on information on the start and end dates or continuation of treatment with Venetocalx 2. Patients participating in other clinical trials

Design outcomes

Primary

Measure	Time frame
The frequency of uMRD at 24 months (+3 months) of treatment with Venetoclax plus/minus Rituximab	—

Secondary

Measure	Time frame
The frequency of L-MRD (Low-Minimal/Measurable Residual Disease) at 24 months (+3 months) of treatment with Venetoclax plus/minus Rituximab	—

Countries

Japan

Contacts

Public ContactRisa Takenaka

AbbVie GK Oncology, Medical Affairs, Medical

risa.takenaka@abbvie.com03-4577-1111

Outcome results